Liquidia Technologies, Inc. (LQDA)

Liquidia Technologies’ mission is to transform patients’ lives with precise drug particles.

Healthcare organizations of all types and sizes are experiencing unprecedented market pressure to deliver better results at reduced costs. Liquidia is actively tackling some of those challenges.

Liquidia’s method for precisely engineering drug particles to new specification can enhance the therapeutic potential of the molecule for the patient, while minimizing risk and reducing time to market. PRINT® technology gives the pharmaceutical industry the power to produce precise drug particles, clinically-effective products at scale, and in some cases reduce manufacturing complexity and cost.

Liquidia’s proprietary PRINT technology brings the pharmaceutical industry the ability to design drug particles uniformly and in a wide variety of compositions, size and shapes. This novel process can optimize the performance of existing or new therapeutics, whether they are based on small molecules, peptides or biologics. The end result? Medications can work as planned, the first time around, helping patients get better and feel better faster.

Liquidia is applying PRINT technology toward internal product development opportunities. The pipeline strategy is focused on improving currently approved products in order to minimize development risk and increase speed to market.

By leveraging PRINT technology, Liquidia’s business model is highly capital efficient in the following ways:

• Liquidia is able to improve existing drugs to reach their full therapeutic potential, without having to incur all of the R&D expenses of a truly novel molecule.
  PRINT is a cost-effective, elegant and simple manufacturing process that can create significant improvement in the performance of existing medicines.

Current product candidates in clinical development span LIQ861 for pulmonary arterial hypertension (PAH) and LIQ865 for local, post-operative pain. Liquidia’s partners including leading pharmaceutical companies such as GlaxoSmithKline, are exploring ways to leverage PRINT technology for new therapies.

http://liquidia.com/